Efficacy News and Research

RSS

Endo International revenues increase $719M to 1% in Q2 2014

Endo International plc today reported second quarter 2014 revenues of $719 million, an increase of 1 percent compared to second quarter 2013 revenues of $712 million.

31 Jul 2014

ChromaDex to provide Murdoch Childrens Research Institute with NR ingredient for research use

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia.

31 Jul 2014

Study to measure attitudes toward e-cigarettes among physicians treating adult smokers

Physicians are increasingly discussing and recommending electronic cigarettes (e-cigarettes) as cessation devices for their patients, but more research needs to be done on their efficacy and safety, according to a new survey of North Carolina physicians published in PLOS ONE.

31 Jul 2014

Washington bioengineers discover potential method to protect women from contracting HIV

Soon, protection from HIV infection could be as simple as inserting a medicated, disappearing fabric minutes before having sex.

31 Jul 2014

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

31 Jul 2014

Acupuncture helps cut fatigue, anxiety and depression in breast cancer patients using aromatase inhibitors

Use of electroacupuncture (EA) - a form of acupuncture where a small electric current is passed between pairs of acupuncture needles - produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs) to treat breast cancer.

31 Jul 2014

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending.

31 Jul 2014

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone).

30 Jul 2014

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1).

29 Jul 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

29 Jul 2014

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet.

29 Jul 2014

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union.

29 Jul 2014

Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

Veloxis Pharmaceuticals A/S and Chiesi Farmaceutici S.p.A. today announced that the European Commission (EC) has granted marketing authorization for Envarsus for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union.

28 Jul 2014

FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.

28 Jul 2014

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated for patients infected with the genotype 1 virus. Telaprevir is available in Trinidad under the trade brand INCIVO®.

26 Jul 2014

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil.

26 Jul 2014

Trials show immunizations are effective in adults

As kids prepare to head back to school, required immunizations are typically on the to-do list, but getting potentially lifesaving vaccines should not end when adulthood begins, says one University of Alabama at Birmingham infectious diseases expert.

26 Jul 2014

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown.

26 Jul 2014

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union.

25 Jul 2014

Efficacy News and Research

Endo International revenues increase $719M to 1% in Q2 2014

ChromaDex to provide Murdoch Childrens Research Institute with NR ingredient for research use

Study to measure attitudes toward e-cigarettes among physicians treating adult smokers

Washington bioengineers discover potential method to protect women from contracting HIV

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Acupuncture helps cut fatigue, anxiety and depression in breast cancer patients using aromatase inhibitors

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

EMD Serono begins MSB0010718C Phase II study in mMCC patients

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Trials show immunizations are effective in adults

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

EMA recommends full marketing approval for IMBRUVICA in the European Union

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News